Possible acute rejection associated with the use of the new antihepatitis C virus medications

Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019
Materias:	acute rejection anti-hepatitis c virus medication daclatasvir direct-acting antiviral agents kidney transplant sofosbuvir Medicine R
Acceso en línea:	https://doaj.org/article/f31e5abbef6b427fbb755c5d33f5dd8e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f31e5abbef6b427fbb755c5d33f5dd8e
record_format	dspace
spelling	oai:doaj.org-article:f31e5abbef6b427fbb755c5d33f5dd8e2021-12-02T17:58:44ZPossible acute rejection associated with the use of the new antihepatitis C virus medications2231-07702249-446410.4103/AJM.AJM_171_17https://doaj.org/article/f31e5abbef6b427fbb755c5d33f5dd8e2019-01-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/AJM.AJM_171_17https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies.Khaled Ar KarkoutSaleema Al SherifQutaiba HusseinAlia AlbawardiYousef BoobesThieme Medical and Scientific Publishers Pvt. Ltd.articleacute rejectionanti-hepatitis c virus medicationdaclatasvirdirect-acting antiviral agentskidney transplantsofosbuvirMedicineRENAvicenna Journal of Medicine, Vol 9, Iss 01, Pp 32-34 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute rejection anti-hepatitis c virus medication daclatasvir direct-acting antiviral agents kidney transplant sofosbuvir Medicine R
spellingShingle	acute rejection anti-hepatitis c virus medication daclatasvir direct-acting antiviral agents kidney transplant sofosbuvir Medicine R Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes Possible acute rejection associated with the use of the new antihepatitis C virus medications
description	Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies.
format	article
author	Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes
author_facet	Khaled Ar Karkout Saleema Al Sherif Qutaiba Hussein Alia Albawardi Yousef Boobes
author_sort	Khaled Ar Karkout
title	Possible acute rejection associated with the use of the new antihepatitis C virus medications
title_short	Possible acute rejection associated with the use of the new antihepatitis C virus medications
title_full	Possible acute rejection associated with the use of the new antihepatitis C virus medications
title_fullStr	Possible acute rejection associated with the use of the new antihepatitis C virus medications
title_full_unstemmed	Possible acute rejection associated with the use of the new antihepatitis C virus medications
title_sort	possible acute rejection associated with the use of the new antihepatitis c virus medications
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2019
url	https://doaj.org/article/f31e5abbef6b427fbb755c5d33f5dd8e
work_keys_str_mv	AT khaledarkarkout possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT saleemaalsherif possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT qutaibahussein possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT aliaalbawardi possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications AT yousefboobes possibleacuterejectionassociatedwiththeuseofthenewantihepatitiscvirusmedications
_version_	1718379024067067904

Possible acute rejection associated with the use of the new antihepatitis C virus medications

Ejemplares similares